Stuart L. Goldstein, MD, FAAP, FNKF
- Clark D. West Endowed Chair
- Director, Center for Acute Care Nephrology
- Medical Director, Pheresis Service
- Co-Director, Heart Institute Research Core
- Professor, UC Department of Pediatrics
- stuart.goldstein@cchmc.org
- Board Certified
About
Biography
As a pediatric kidney specialist, I treat children and adolescents in all areas of pediatric nephrology. These include general nephrology, acute kidney injury (AKI), dialysis, transplantation and tuberous sclerosis. I also consult on fetal care if there is a problem with the unborn baby’s kidneys.
I was drawn to the field of nephrology by the opportunity it presents to improve the outcomes for children with kidney problems. Working with children and their families, I help patients reach their full potential. Nephrology also allows me to practice across the entire spectrum of pediatric illness, from acute critical care, to chronic care and outpatient care.
My research is focused on short- and long-term outcomes for children who have AKI and those who are at risk for AKI. I’m interested in AKI epidemiology and outcomes, acute renal replacement therapy and investigation of novel urinary AKI biomarkers in the pediatric population.
In 2012, I established Prospective Pediatric AKI Research Group (ppAKI-RG). The ppAKI-RG is comprised of more than 60 centers around the world with the goal of improving outcomes for the child with, or at-risk for, AKI. This consortium focuses on multicentered research studies that are dedicated to understanding and treating AKI in pediatric patients. This group has completed three major, unprecedented national and international studies to accurately characterize pediatric AKI epidemiology, reduce AKI and improve patient outcomes.
I also developed the only pediatric-specific, acute-care nephrology subspecialty fellowship with graduates who are now leaders in the field of pediatric AKI.
MD: Columbia College of Physicians and Surgeons, New York, NY, 1990
Residency: Baylor College of Medicine, Houston, TX
Fellowship: Pediatric Nephrology, Children's Hospital, Boston, MA
Interests
Acute kidney injury; continuous renal replacement therapy; cardio-renal syndrome; nephrotoxic medication associated morbidity
Interests
Acute kidney injury epidemiology and biomarkers; heart failure associated chronic kidney disease; nephrotoxic medication associated acute kidney injury reduction
Research Areas
Additional Languages
Spanish
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Early post-approval experience of the selective cytopheretic device surveillance registry for pediatric AKI requiring kidney replacement therapy. Pediatric Nephrology. 2026; 41(7):2205-2212.
External Validation, Molecular Signatures, and Therapeutic Relevance of Pediatric Sepsis-Associated Acute Kidney Injury Subphenotypes. Critical Care Medicine. 2026; 54(7):1680-1690.
Preventing pediatric acute kidney injury: is it even possible? Pediatric Nephrology. 2026.
Neonatal AKI Definition: Is the perfect definition attainable or even desirable? Proceedings from the First International Neonatal Nephrology Symposium. Pediatric Research. 2026; 99(5):1674-1677.
Conventional cytotoxic chemotherapy-associated nephrotoxicity: consensus report of the 34th Acute Disease Quality Initiative (ADQI) Workgroup. Kidney International. 2026; 109(6):1114-1124.
Extracorporeal membrane oxygenation, acute kidney injury, fluid balance, and continuous renal replacement therapy: Acute Disease Quality Initiative (ADQI) and Extracorporeal Life Support Organization (ELSO) joint consensus conference. Intensive Care Medicine. 2026; 52(6):1175-1195.
Urine NGAL adds to serum creatinine in predicting cefepime clearance in critically ill children at high risk of acute kidney injury. International Journal of Antimicrobial Agents. 2026; 67(5):107741.
Serum renin levels refine acute kidney injury prediction in critically ill children. Pediatric Nephrology. 2026; 41(4):1203-1211.
The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup. Nature Reviews Nephrology. 2026; 22(4):283-300.
Accuracy of Point-of-Care Transdermal GFR Methodology. Kidney International Reports. 2026; 11(4):103797.
From the Blog
Kidney Injury Device Fares Well in Post-Approval Tracking Study
Stuart L. Goldstein, MD, FAAP, FNKF2/9/2026
First Acute Kidney Injury Diagnostic Test Wins FDA Clearance
Stuart L. Goldstein, MD, FAAP, FNKF, Prasad Devarajan, MD, FAAP, FASN12/7/2023
Improved Piperacillin Dosing May Lower Risk of AKI in Critically Ill Patients
Stuart L. Goldstein, MD, FAAP, FNKF, Sonya Tang Girdwood, MD, PhD2/1/2023
Global Panel Addresses Lack of Care Standards for Children with Acute Kidney Injury
Stuart L. Goldstein, MD, FAAP, FNKF9/1/2022
For Continuous Dialysis Nafamostat Shows Similar Efficacy, Lower Toxicity, Lower Costs vs. Citrate
Stuart L. Goldstein, MD, FAAP, FNKF4/5/2022
Better AWAREness of Acute Kidney Injury Could Transform Intensive Care
Stuart L. Goldstein, MD, FAAP, FNKF6/30/2019
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 2026 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey